eligibility_summary
Eligible: >6 months, tumor cells express CD7±other antigens, KPS>80, life expectancy >3 mo, adequate marrow/organ function (EF≥50%, O2 sat≥90%, Cr≤2.5×ULN, AST/ALT≤3×ULN, bilirubin≤2.0 mg/dL, Hgb≥80 g/L), no cell-separation contraindications, able to consent. Exclude: severe/uncontrolled illness or infection, HIV/HCV, pregnant/nursing, systemic steroids within 1 wk, prior gene therapy, likely noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/Intervention: Universal 4SCAR7U CD7-specific CAR T cells—biological, gene‑modified, off‑the‑shelf allogeneic T cells produced in bulk. Mechanism: a lentiviral chimeric antigen receptor redirects T cells to recognize CD7 on malignant cells, triggering antigen‑specific activation, expansion, and cytotoxic killing independent of the native TCR, designed for persistence to control CD7+ disease. Cells/Pathways targeted: CD7 antigen on T‑lineage malignancies (T‑ALL/T‑LBL, T‑cell lymphomas), NK cell lymphomas, and subsets of AML, impacts the CD7 pathway expressed early through terminal T‑cell development and depletes CD7+ T/NK lineage compartments. The study may also combine with alternative CAR targets.